The present invention discloses the use of sea cucumber glycosaminoglycan in preparing medicine animal testing has shown that for a weight average molecular weight exceeding 54,500Da of depolymerized sea cucumber glycosaminoglycan or of one or more segments of natural molecular segments of sea cucumber glucosaminoglycan, the anti-coagulant activity thereof shows dose-dependency in contrast to heparin and low molecular weight heparin, the dose-dependency thereof increases the incremental easing of blood coagulation, and, with an identical dose size, as weight average molecular weight increases, the onset time is delayed while the duration of efficacy is increased. For certain dosages, natural molecular segment sea cucumber glycosaminoglycan can have a duration of efficacy of up to 16 hours, and can be used for preparing medicine for preventing and treating arterial thromboembolic diseases. The present invention has a higher level of safety when compared with heparin-type drugs and vitamin K antagonist-type drugs. In clinical use, the present invention has a wide treatment window for thromboembolic disease, has a high level of safety, and has good research and development value.La présente invention concerne lutilisation dun glycosaminoglycane de concombre de mer pour la préparation dun médicament des tests sur animaux ont révélé que pour un poids moléculaire moyen en poids dépassant 54 500 Da de glycosaminoglycane de concombre de mer dépolymérisé ou dun ou de plusieurs segments de segments moléculaires naturels de glycosaminoglycane de concombre de mer, lactivité anticoagulante de ce dernier révèle une dépendance au dosage contrairement à lhéparine et à lhéparine de faible poids moléculaire, dont la dépendance au dosage augmente la promotion incrémentielle de la coagulation sanguine et, à dosage identique, puisque le poids moléculaire moyen en poids augmente, le moment dapparition est retardé tandis que la durée defficacité augmente. À certains dosages, le glycosamin
